U.S. National Institutes of Health
U.S. National Institutes of Health


IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
190261190261Familial Aggregation of Barrett's EsophagusActive, not recruitingNo Results AvailableBarrett's Esophagus|Esophageal Neoplasmhttps://ClinicalTrials.gov/show/NCT00058877
190262190262The HIP Impact Protection Program (HIP PRO)CompletedNo Results AvailableHip FracturesDevice: Energy absorbing and distributing trochanteric padhttps://ClinicalTrials.gov/show/NCT00058864
190263190263Massage Therapy for Breast Cancer Treatment-Related Swelling of the ArmsCompletedNo Results AvailableLymphedemaProcedure: Manual lymph drainage|Procedure: Combined physiotherapy|Procedure: Compression bandaginghttps://ClinicalTrials.gov/show/NCT00058851
190264190264Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's DiseaseCompletedNo Results AvailableParkinson DiseaseDrug: sumanirolehttps://ClinicalTrials.gov/show/NCT00058838
190265190265Stem Cell Transplant for Hematologic DiseasesTerminatedNo Results AvailableHematologic MalignanciesBiological: Campath 1H|Drug: Fludarabine|Procedure: Stem Cell Transplant|Radiation: Total Body Irradiation (TBI)|Drug: FK506 (Tacrolimus) or Cyclosporinehttps://ClinicalTrials.gov/show/NCT00058825
190266190266Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow GraftsCompletedNo Results AvailableEpstein-Barr Virus InfectionsBiological: EBV specific T cellshttps://ClinicalTrials.gov/show/NCT00058812
190267190267Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor VaccineCompletedNo Results AvailableLeukemiaBiological: Tumor Vaccine: CD40 LIGAND AND IL-2 GENE MODIFIED AUTOLOGOUS SKIN FIBROBLASTS AND TUMOR CELLShttps://ClinicalTrials.gov/show/NCT00058799
190268190268Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor CellsCompletedNo Results AvailableChronic Lymphocytic B-LeukemiaBiological: Injection of IL-2-secreting CD40L-expressing autologous B-CLL cellshttps://ClinicalTrials.gov/show/NCT00058786
190269190269Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin DiseaseTerminatedNo Results AvailableHodgkin Disease|Non-Hodgkins LymphomaDrug: Infusion of EBV Specific Cytotoxic T-Lymphocyteshttps://ClinicalTrials.gov/show/NCT00058773
190270190270Delaying Sexual Activity in African American Adolescent GirlsRecruitingNo Results AvailableAdolescent Behavior|Sex BehaviorBehavioral: NIA intervention (after school health promotion didactic program)https://ClinicalTrials.gov/show/NCT00058760
190271190271AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevecâ„¢TerminatedNo Results AvailableLeukemia, Myeloid, ChronicDrug: Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevecâ„¢.https://ClinicalTrials.gov/show/NCT00058747
190272190272Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected PatientsCompletedNo Results AvailableHIV InfectionsBiological: Dendritic Cells Pulsed with HIV antigenshttps://ClinicalTrials.gov/show/NCT00058734
190273190273Single Photon Emission Computed Tomography to Study Receptors in Parkinson's DiseaseCompletedNo Results AvailableParkinson DiseaseDrug: I-123-5-IA85380https://ClinicalTrials.gov/show/NCT00058721
190274190274Genetic Factors in Age-Related Macular DegenerationRecruitingNo Results AvailableMacular Degenerationhttps://ClinicalTrials.gov/show/NCT00058695
190275190275Anidulafungin Versus Fluconazole in the Treatment of CandidemiaCompletedNo Results AvailableCandida|CandidiasisDrug: Anidulafunginhttps://ClinicalTrials.gov/show/NCT00058682
190276190276CVD Risk Factors and Sexual Identity in WomenCompletedNo Results AvailableCardiovascular Diseases|Heart Diseases|Coronary Diseasehttps://ClinicalTrials.gov/show/NCT00058669
190277190277Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) PatientsCompletedNo Results AvailableChronic Lymphocytic LeukemiaProcedure: Infusion of Activated & Expanded Autologous T Cellshttps://ClinicalTrials.gov/show/NCT00058656
190278190278Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGELCompletedNo Results AvailableEpstein-Barr Virus-Related Hodgkin Lymphoma|Epstein-Barr Virus-Related Non-Hodgkin Lymphoma|EBV Positive Plasma Cell NeoplasmGenetic: Injection of EBV Specific CTLshttps://ClinicalTrials.gov/show/NCT00058617
190279190279Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).CompletedNo Results AvailableEpstein-Barr Virus Infections|Lymphoproliferative DisordersBiological: Intravenous injection of EBV specific CTLshttps://ClinicalTrials.gov/show/NCT00058604
190280190280Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs)CompletedNo Results AvailableEpstein-Barr Virus InfectionsBiological: Intravenous injection of EBV specific CTLShttps://ClinicalTrials.gov/show/NCT00058591
190281190281Stem Cell Transplant to Treat Patients With Systemic SclerosisCompletedNo Results AvailableSystemic SclerosisDrug: Cyclophosphamide|Drug: Mesna|Drug: G-CSF|Procedure: Leukopheresis|Procedure: Total Body Irradiationhttps://ClinicalTrials.gov/show/NCT00058578
190282190282A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian CancerCompletedHas ResultsOvarian CancerDrug: Pertuzumab (rhuMAb 2C4)https://ClinicalTrials.gov/show/NCT00058552
190283190283Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate CancerCompletedHas ResultsProstate CancerDrug: rhuMAb 2C4 (pertuzumab)https://ClinicalTrials.gov/show/NCT00058539
190284190284A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast CancerCompletedNo Results AvailableNeoplasms|Breast CancerBiological: Immunotherapeutic SB719125 (Primary)https://ClinicalTrials.gov/show/NCT00058526
190285190285Epirubicin and Thalidomide in Treating Patients With Liver CancerCompletedNo Results AvailableLiver CancerDrug: epirubicin hydrochloride|Drug: thalidomidehttps://ClinicalTrials.gov/show/NCT00058487
190286190286Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal CancerActive, not recruitingNo Results AvailableColorectal CancerDrug: capecitabine|Drug: fluorouracil|Drug: oxaliplatin|Radiation: radiation therapyhttps://ClinicalTrials.gov/show/NCT00058474
190287190287Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNo Results AvailableB-cell Childhood Acute Lymphoblastic Leukemia|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|L3 Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|RecurrentDrug: ifosfamide|Drug: etoposide|Biological: rituximab|Drug: carboplatin|Biological: filgrastim|Drug: methotrexate|Drug: cytarabine|Other: laboratory biomarker analysishttps://ClinicalTrials.gov/show/NCT00058461
190288190288S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)TerminatedNo Results AvailablePenile CancerDrug: docetaxelhttps://ClinicalTrials.gov/show/NCT00058448
190289190289Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerCompletedNo Results AvailableFallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity CancerBiological: abagovomabhttps://ClinicalTrials.gov/show/NCT00058435
190290190290Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell LymphomaActive, not recruitingNo Results AvailableLymphomaBiological: darbepoetin alfa|Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: indium In 111 ibritumomab tiuxetan|Radiation: yttrium Y 90 ibritumomab tiuxetanhttps://ClinicalTrials.gov/show/NCT00058422

* Görseller ve İçerik tekif hakkına sahip olabilir